5382-17-2

Basic information

• Product Name: 4-Hydroxypiperidine hydrochloride
• Synonyms: PIPERIDIN-4-OL HYDROCHLORIDE;TIMTEC-BB SBB004192;4-HYDROXYPIPERIDINE HYDROCHLORIDE;4-PIPERIDINOL HYDROCHLORIDE;4-PIPIRIDINOL HYDROCHLORIDE;4-Hydroxypiperidine HCl;4-hydroxypiperidinium chloride;piperidin-4-ol hcl
• CAS NO: 5382-17-2
• Molecular Formula: C₅H₁₁NO*ClH
• Molecular Weight: 137.61
• EINECS: 226-374-7
• Product Categories: Piperidine
• Mol File: 5382-17-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 155-157 °C(lit.)
• Boiling Point: 222 °C at 760 mmHg
• Flash Point: 107.8 °C
• Appearance: /
• Vapor Pressure: 0.0214mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• Solubility: methanol: soluble25mg/mL, clear, colorless
• Water Solubility: very faint turbidity
• BRN: 3908995
• CAS DataBase Reference: 4-Hydroxypiperidine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Hydroxypiperidine hydrochloride(5382-17-2)
• EPA Substance Registry System: 4-Hydroxypiperidine hydrochloride(5382-17-2)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• F: 3
• Hazardous Substances Data: 5382-17-2(Hazardous Substances Data)

Usage

Chemical Properties

White powder

Uses

Different sources of media describe the Uses of 5382-17-2 differently. You can refer to the following data:
1. 4-Hydroxypiperidine, HCl
2. 4-Hydroxypiperidine hydrochloride is suitable for use in the Ugi-multi component reaction (MCR) to study the use of miniaturised-synthesis and Total Analysis System (mSYNTAS) in solution phase synthesis and on-line analysis of Ugi-MCRs. It may be used in the synthesis of acetic acid-piperidine-4-yl ester.

General Description

4-Hydroxypiperidine hydrochloride is a piperidine derivative. The synthesis of 4-hydroxypiperidine has been reported. 4-Hydroxypiperidine participates in the synthesis of 4-(4′-hydroxypiperidino)-4-phenylcyclohexanol and 1-(4-hydroxypiperidino)cyclohexanecarbonitrile. 4-Hydroxypiperidine is the starting material for the synthesis of Sibrafiban and Lamifiban, two non-peptidefibrinogen receptor.

InChI:InChI=1/C5H11NO.ClH/c7-5-1-3-6-4-2-5;/h5-7H,1-4H2;1H

Upstream product

• 626-64-2 pyridin-4-ol 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 186431-51-6 (S)-[1-Benzyl-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 332135-25-8 4-benzyl-5-bromo-2-(4-hydroxypiperidino)pyridine 
• 95798-23-5 1-(benzyloxycarbonyl)-4-hydroxypiperidine 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 
• 186431-68-5 [(S)-1-(4-Fluoro-benzyl)-2-(4-hydroxy-piperidin-1-yl)-2-oxo-ethyl]-carbamic acid tert-butyl ester 
• 60756-86-7 4-hydroxypiperidinocyclohexyl carbonitrile 
• 848438-60-8 N-chloroacetyl-4-hydroxypiperidine 
• 332133-32-1 3-[4-Benzyl-2-(4-hydroxypiperidino)-5-pyridyl]ethynyl-3-quinuclidinol 
• 800397-99-3 5-chloro-1H-pyrrolo[2,3-c]pyridine-2-carboxylic acid[1-(S)-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]amide 
• 4045-22-1 N-acetyl-4-hydroxypiperidine 

Relevant articles and documents

Two polymorphs of 4-hydroxypiperidine with different NH configurations

4-Hydroxypiperidine 1 exists in two crystal forms, tetragonal 1t, space group P4ˉ21c and orthorhombic 1o, space group Fdd2, both with one molecule in the asymmetric unit. The latter form was obtained only rarely and in small quantities. In form 1t, the NH hydrogen is axial, whereas in 1o it is equatorial; the OH group is equatorial in both structures. The packing of both forms involves one hydrogen bond N-H?O and one O-H?N. In solution, NMR spectra indicate the presence of separate axial and equatorial forms (with respect to the OH group) below ca. -53 °C; however, not even at -104 °C, the lowest temperature reached, could any freezing out of the inversion at nitrogen be observed, implying that the energy barrier for this process is (as expected) small. We were unable to convert 1t, which appears to be the more stable form over the whole temperature range up to the melting point, to 1o by heating or via melting and re-cooling (or by any other method), perhaps because the hydrogen-bonding pattern is resistant to change. The crystalline forms 1t and 1o, despite being polymorphs of 1 with different NH configurations, should not be described as "configurational polymorphs" because of the facile interconversion in solution.

BENZOPIPERIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND HEMOGLOBINOPATHIES

A compound of formula I: (I) wherein: n is 1 or 2; p is 0 or 1; R1a, R1b, R1c and R1d are independently selected from H, halo, C1-4 alkyl, C1-4 fluoroalkyl, C3-4 cycloalkyl, C1-4 alkyloxy, NH-C1-4 alkyl and cyano; R2a and R2b are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2c and R2d are independently selected from the group consisting of: (i) F; (ii) H; (iii) Me; and (iv) CH2OH; R2e is H or Me; R3a and R3b are independently selected from H and Me; R4 is either H or Me; R5 is either H or Me; R6a and R6b are independently selected from H and Me; A is either (IIa), where R7a is selected from N-linked N-containing C5-7 heterocycyl and (A); or (ii) (IIb), where X is selected from CH2, N H and O, one of R8a and R8b is selected from CI and ethoxy and the other of R8a and R8b is H.

SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS

The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.